Form 4: Generation Bio Co. Executive Matthew Norkunas Reports Stock Transactions

Matthew Norkunas, Chief Financial Officer of Generation Bio Co., reports the vesting and subsequent sale of restricted stock units.

Summary

• On April 15, 2024, Matthew Norkunas, the Chief Financial Officer of Generation Bio Co., engaged in transactions involving the company's common stock.
• These transactions included the vesting of 1,674 and 1,673 restricted stock units (RSUs) and the subsequent disposition of 492 shares each to cover tax obligations at a price of $3.7 per share.
• Following these transactions, Norkunas directly owns 52,622 shares of Generation Bio Co. common stock and 5,019 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative implications for the company's performance or outlook.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the biotechnology industry. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a standard part of compensation in publicly traded companies, particularly in the biotech sector.
• Vesting schedules for restricted stock units typically range from two to four years, aligning with industry norms for incentivizing long-term performance.
• Similar filings are regularly made by executives at comparable companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics.

Stakeholder Impact

• The transactions have a minimal impact on shareholders, as they represent a small percentage of the total outstanding shares.
• The disclosure provides transparency to stakeholders regarding executive compensation and ownership.

Key Dates